Primary Cutaneous B-cell Lymphoma Leg-type Related to a Tumour Necrosis Factor Alpha Inhibitor

Authors

  • Samy Belkaïd Centre Hospitalier de Valence, Service de dermatologie, Valence, France
  • Brigitte Balme 2. Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’anatomie-pathologie, Pierre-Bénite, France
  • Olivier Harou 2. Hospices Civils de Lyon, Hôpital Lyon Sud, Service d’anatomie-pathologie, Pierre-Bénite, France
  • Joann Le Borgne de la Villandré Centre Hospitalier de Valence, Service de dermatologie, Valence, France
  • Chloé Wirbel Centre Hospitalier de Valence, Service de dermatologie, Valence, France
  • Stéphane Dalle Hospices Civils de Lyon, Hôpital Lyon Sud, Service de dermatologie, Pierre-Bénite, France
  • Florent Grange Centre Hospitalier de Valence, Service de dermatologie, Valence, France

DOI:

https://doi.org/10.2340/actadv.v102.348

Keywords:

TNF-alpha inhibitors, adalimumab, primary cutaneous B-cell lymphoma, PCBCL-LT

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Lakatos PL, Miheller P. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? Curr Drug Targets 2010; 11: 179-186.

https://doi.org/10.2174/138945010790309867

Hruska CJ, Bertoli RJ, Young YD, Burkhart PH, Googe PB. Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab. JAAD Case Rep 2015; 1: 56-59.

https://doi.org/10.1016/j.jdcr.2014.12.006

Martinez-Escala ME, Posligua AL, Wickless H, Rutherford A, Sable KA, Rubio-Gonzalez B, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 2018; 78: 1068-1076.

https://doi.org/10.1016/j.jaad.2017.12.068

Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF Inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. J Crohns Colitis 2021; 15: 840-859.

https://doi.org/10.1093/ecco-jcc/jjaa186

Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Ghogomu ET, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 2015; 4: CD005468.

https://doi.org/10.1002/14651858.CD005468.pub2

Grange F, Beylot-Barry M, Courville P, Maubec E, Bagot M, Vergier B, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007; 143: 1144-1150.

https://doi.org/10.1001/archderm.143.9.1144

Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol 2014; 150: 535-541.

https://doi.org/10.1001/jamadermatol.2013.7452

Graham PM, Richardson AS, Schapiro BL, Saunders MD, Stewart DM. Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type with significant T-cell immune response. JAAD Case Rep 2018; 4: 305-309.

https://doi.org/10.1016/j.jdcr.2017.10.012

Zhao J, Han B, Shen T, Zhao Y, Wang T, Liu Y, et al. Primary cutaneous diffuse large B-cell lymphoma (leg type) after renal allograft: case report and review of the literature. Int J Hematol 2009; 89: 113-117.

https://doi.org/10.1007/s12185-008-0201-5

Koens L, Senff NJ, Vermeer MH, Willemze R, Jansen PM. Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: a clinicopathologic and immunophenotypical study of 10 cases. Am J Surg Pathol 2014; 38: 999-1006.

https://doi.org/10.1097/PAS.0000000000000225

Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, et al. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol 2014; 150: 1173-1179.

https://doi.org/10.1001/jamadermatol.2014.821

Downloads

Published

2022-04-04

How to Cite

Belkaïd, S., Balme, B., Harou, O., Le Borgne de la Villandré, J., Wirbel, C., Dalle, S., & Grange, F. (2022). Primary Cutaneous B-cell Lymphoma Leg-type Related to a Tumour Necrosis Factor Alpha Inhibitor. Acta Dermato-Venereologica, 102, adv00688. https://doi.org/10.2340/actadv.v102.348